| 1 | 26029165 | Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines. | Front Endocrinol (Lausanne) | 2015 |
1 |
| 2 | 28453463 | The IGF-I/JAK2-STAT3/miR-21 signaling pathway may be associated with human renal cell carcinoma cell growth. | Cancer Biomark | 2017 Jul 4 |
1 |
| 3 | 28583713 | IGF-1R signalling contributes to IL-6 production and T cell dependent inflammation in rheumatoid arthritis. | Biochim Biophys Acta Mol Basis Dis | 2017 Sep |
2 |
| 4 | 29731870 | IGF-1-induced MMP-11 expression promotes the proliferation and invasion of gastric cancer cells through the JAK1/STAT3 signaling pathway. | Oncol Lett | 2018 May |
3 |
| 5 | 29736736 | The Medial Septum Is Insulin Resistant in the AD Presymptomatic Phase: Rescue by Nerve Growth Factor-Driven IRS<sub>1</sub> Activation. | Mol Neurobiol | 2019 Jan |
3 |
| 6 | 30229539 | Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells. | Horm Cancer | 2018 Dec |
4 |
| 7 | 31042587 | IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. | Cancer Lett | 2019 Aug 1 |
9 |
| 8 | 32296029 | NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2<sup>V617F</sup>-positive myeloproliferative neoplasm cells. | Signal Transduct Target Ther | 2020 Jan 24 |
16 |
| 9 | 33007330 | FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling. | Biochim Biophys Acta Mol Cell Res | 2021 Jan |
4 |
| 10 | 33403501 | NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. | Invest New Drugs | 2021 Jun |
4 |
| 11 | 34238066 | NT157 Inhibits HCC Migration via Downregulating the STAT3/Jab1 Signaling Pathway. | Technol Cancer Res Treat | 2021 Jan-Dec |
2 |